Category: CareFusion Corp.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
Long time House Rep. and Senate hopeful Ed Markey (D-Mass.) says he’s willing to reduce the medical device tax in exchange for fewer tax breaks for oil companies.
MASSDEVICE ON CALL — During the June 5 debate for the Mass. Senate seat, Rep. Ed Markey (D) promised to introduce an amendment to the Affordable Care Act to reduce the medical device tax.
Markey said he would make up the losses with decreased tax breaks to oil companies. While he affirmed his support for healthcare reform during the debate, he reminded voters that he opposes the device tax.
Smiths Group confirms that it's gotten an offer for its medical device division, a deal that some say could be worth more than $2.6 billion.
European engineering conglomerate Smiths Medical confirmed late last week that it had received an offer for its medical division, refusing to divulge any other details of the "early stage" discussions.
Groups purporting to have inside information about the talks have reported that Smiths Group has taken steps to align Smiths Medical as a stand-alone entity and that it may sell for more than $2.62 billion (£2 billion).
Natus Medical beats Wall Street's earnings forecast with a 1,000-fold profit surge on record sales, prompting the medical device company to raise its earnings forecast for the rest of the year.
Natus Medical (NSDQ:BABY) reported a 1,000% increase in profits during the 1st quarter, handily beating Wall Street's earnings-per-share forecast in the process.
CareFusion officials said sales at the San Diego, Calif. -based medical device company will be lower than previously expected during 2013.
CareFusion (NYSE:CFN) rang up a nearly 163% increase in profits during its fiscal 3rd quarter, topping analysts' expectations but disappointing The Street with lowered fiscal 2013 sales guidance.
San Diego, Calif.-based medical device company CareFusion agrees to pay $41 million to end 2-year investigation into its marketing practices for ChloraPrep skin preparation product
CareFusion (NYSE:CFN) agreed to pay $41 million to settle a 2-year federal probe into the sales and marketing of its ChloraPrep line of antiseptic wipes.